Regulators are trying to push drug development into a post-animal testing era. Meanwhile, a Jennifer Doudna-founded company is edging toward successful CAR-T therapy done in vivo, and a “triple-G” drug from Eli Lilly delivers strong results.
Lastly, don’t forget that today is STAT’s Breakthrough Summit East! Virtual tickets still available.
In-vivo CAR-T inches toward clinical reality
A new Nature paper from Azalea Therapeutics, a spinout of Jennifer Doudna’s lab, offers an early but notable step toward in vivo CAR-T — engineering cancer-fighting T cells directly inside the body rather than through the laborious lab-driven process.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
